Buoyed by survival data, Ohio State inventors revive cancer-hunting drug that launched Neoprobe

Story excerpt provided by Columbus Business First.

Written by Carrie Ghose.

Inventors are reviving a cancer-hunting drug – the founding technology of the former Neoprobe Corp. – that federal regulators put in hibernation 20 years ago.

Their new company, Enlyton Ltd., licensed an improved version of the imaging agent and other technology from Ohio State University and are preparing for clinical trials toward applying for U.S. Food and Drug Administration approval.

The founding researchers this month hired CEO Dr. Wayne Poll, a surgeon who founded Minimally Invasive Devices Inc., one of Central Ohio’s most successful companies at raising venture capital until it was sold this summer.

Click here to read the complete article.

Originally published October 9, 2017.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: